Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Morphic Therapeutic

Morphic Therapeutic
2014 FOUNDED
PUBLIC STATUS
61-70 EMPLOYEES
MORF STOCK SYMBOL
$19.69 SHARE PRICE (As of Friday Closing)
Description

Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 35 Gatehouse Drive, A2
  • Waltham, MA 02451
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Morphic Therapeutic’s full profile, request a free trial.

Morphic Therapeutic Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$12.03 - $33.50 $600M $20.14 -$3.04 54.5K 30.5M

Morphic Therapeutic Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
Enterprise Value 521,817
Revenue 20,669 3,358 0
EBITDA (31,783) (24,163) (16,500)
Net Income (28,841) (23,831) (16,920)
Total Assets 260,079 189,305 23,242
Total Debt 0 0 630
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Morphic Therapeutic Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Morphic Therapeutic‘s full profile, request access.

Request full access to PitchBook

Morphic Therapeutic Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Encycle Therapeutics Formerly VC-backed Toronto, Canada 0 00.000 000000&0 00.000
0000000 0000000000 Corporation San Diego, CA 00 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Laval, Canada 000 00000 000000000 00000
000000000 00000000 Venture Capital-Backed Salt Lake City, UT 000 00000 000000000 00000
00000 000000000000 Venture Capital-Backed South San Francisco, CA 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

Morphic Therapeutic Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Morphic Therapeutic‘s full profile, request access.

Request full access to PitchBook

Morphic Therapeutic Executive Team (6)

Name Title Board
Seat
Contact
Info
Praveen Tipirneni MD Chief Executive Officer & Board Member
Bruce Rogers Ph.D Chief Scientific Officer
Alexey Lugovskoy Ph.D Executive
Blaise Lippa Ph.D Head, Chemistry
Robert Farrell Jr. Treasurer & Vice President
You’re viewing 5 of 6 executives. Get the full list »

Morphic Therapeutic Board Members (13)

Name Representing Role Since Contact
Info
Amir Nashat Ph.D Polaris Partners Board Member 000 0000
Gustav Christensen Morphic Therapeutic Chairman & Board Member 000 0000
Joseph Slattery Morphic Therapeutic Board Member 000 0000
Nilesh Kumar Ph.D Novo Holdings Board Member 000 0000
Norbert Bischofberger Ph.D Self Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »